1. The Korean Pharmaceutical Bottle Market in 2026

Korean pharmaceutical packaging is among the most demanding industrial segments globally — and one of the most growing. Korean pharma majors — Daewoong, Yuhan, JW Pharm, Hanmi Pharm, CJ HealthCare, Korea Eundan, and the Donga Otsuka Bacchus / Vita500 OTC franchises — collectively produce over 4 billion plastic primary packaging units annually for domestic and export markets, with Southeast Asian export volumes growing 12–18% per year through 2026.

The packaging segment splits roughly into eye drop and dropper bottles (5–30 ml, typically PE/PET/PP), oral liquid medication bottles (50–250 ml, typically PET/PETG/amber PET), syrup bottles (100–500 ml, often pigmented PET), nasal sprays and inhaler bottles (10–50 ml specialty), and OTC vitamin/supplement bottles (250 ml–2 L, frequently PET). Each segment carries distinct technical and regulatory requirements, but they share a common requirement floor that fundamentally shapes the equipment decision.

For Korean producers planning entry into pharmaceutical packaging — whether as direct producers, contract manufacturers serving Daewoong-tier customers, or upgrading existing food/cosmetic lines into pharma — understanding this requirement floor is the precondition to any honest equipment evaluation. The full landscape of Korean pharma packaging engineering is documented in our 医薬品GMPボトル製造ガイド.

2. Why Two-Step Cannot Serve Pharmaceutical Production

Two-Step reheat blow molding is functionally disqualified from Korean pharmaceutical packaging production for three independent reasons — each one alone sufficient.

Reason 1 — Preform Contamination Pathway

In Two-Step, preforms are ejected into bulk bins after injection, conveyed through warehouse storage (often days or weeks), then fed into the blow stage through bulk feeders that physically contact thousands of preforms during sorting. This contact pathway introduces particulate contamination — fibers, dust, microbial residue — onto preform surfaces that then become bottle interior surfaces. Pharmaceutical regulatory standards require demonstrably controlled contamination pathways; Two-Step’s bulk handling makes this demonstration essentially impossible. The architectural comparison is detailed in our One-Step vs. Two-Step blow molding analysis.

Reason 2 — Surface Quality Insufficient for Sterile Fill

Sterile-fill pharmaceutical applications require bottle interior surfaces with no detectable scratches, no occlusions, and no surface roughness above specified Ra values. Two-Step’s preform bin handling creates micro-scratches that survive blow molding and become permanent surface defects on the finished bottle. For non-sterile OTC products this is acceptable; for sterile-fill eye drops and parenteral packaging, it is disqualifying.

Reason 3 — Thermal Variation Beyond Pharma Tolerance

Two-Step infrared reheat ovens cannot achieve the ±2°C melt temperature precision that pharmaceutical specialty resins demand. Pharma-grade PET, amber PET, and PETG variants have narrower processing windows than commodity PET, and Two-Step’s reheat thermal noise produces unacceptable dimensional and weight variation across cycles.

3. Eye Drop Bottles: The Sterility & Precision Challenge

Eye drop bottles (5–30 ml) are simultaneously the smallest and most demanding pharmaceutical packaging Korean producers manufacture. They require: integral or compatible dropper functionality with precise drop-volume reproducibility (typically 30–50 μL per drop, ±10%), sterile-fill compatibility for unpreserved formulations, dimensional precision allowing reliable closure with pharmaceutical-grade caps, neck-finish thread tolerance under 0.05 mm, optical clarity for visual fill verification, and chemical compatibility with active pharmaceutical ingredients across multi-year shelf life.

Korean Ever-Power’s HGY50-V3-EV precision ISBM platform is purpose-engineered for this segment. The all-servo architecture eliminates any oil contamination pathway. The 4-station thermal architecture with servo gate cutting eliminates gate vestige that would interfere with dropper insertion. Dual-servo clamping delivers the parting-line precision sterile-fill requires. Integrated temperature control supports specialty pharma resins including amber PET (for light-sensitive medications), high-clarity virgin PET (for unpreserved sterile products), and pharmaceutical-grade PETG.

Korean producers serving Daewoong, JW Pharm, and similar majors typically produce eye drop bottles in dedicated cleanroom-integrated lines using the HGY50-V3-EV configured for ISO 7 cleanroom compatibility — ambient air filtration to 99.97% HEPA, machine surface materials selected for cleanability, no exposed lubricants in the production envelope, and zero hydraulic fluid present anywhere in the cycle.

4. Oral Liquid & Syrup Bottles: Material & Migration Compliance

Oral liquid medication and syrup bottles (50–500 ml) face slightly different requirements than eye drops — sterility is generally not required for non-sterile oral products — but introduce additional challenges around chemical compatibility, light protection, and migration testing.

Material Selection for Korean Pharma

Standard PET serves clear oral liquid applications well, with KFDA Article 6 approval and excellent chemical compatibility for most aqueous formulations. Amber PET (with selective UV absorber additives) provides light protection for photo-sensitive medications. PETG offers superior chemical compatibility for some specialty formulations and supports thicker-wall designs for premium-feel OTC products. Pharmaceutical PP supports hot-fill applications for some syrup formulations. For ESG-conscious producers, the K-EPR rPET timeline applies to pharmaceutical packaging on the same schedule as other PET applications.

Migration Testing Requirements

KFDA Article 6, FDA 21 CFR 174-178, and EU 10/2011 all require documented migration testing demonstrating that no resin components migrate into the contained pharmaceutical above specified limits across product shelf life. Migration testing is conducted by certified third-party laboratories using formulation-equivalent simulants under accelerated conditions. Korean Ever-Power machines are validated to support this testing protocol — every production lot can be traced through complete process documentation back to validated machine and mould parameters.

Material selection logic for pharmaceutical applications mirrors the methodology in our PET vs. PETG resin selection guide, with additional weighting toward chemical compatibility and migration profile data.

5. The All-Servo Advantage: Why Hydraulic Is Disqualified

Korean pharmaceutical regulatory inspectors and customer quality auditors look specifically for one thing during equipment audits: any pathway by which non-product-contact substances could potentially contaminate product-contact surfaces. Hydraulic ISBM machines fail this test fundamentally and immediately.

Hydraulic ISBM systems contain 50–200 liters of hydraulic fluid circulating under pressure throughout the machine envelope. Hydraulic seals fail. Hydraulic lines develop pinhole leaks. Hydraulic oil mist becomes airborne under normal operation. Each of these creates a documented contamination pathway between machine fluid and the cleanroom air surrounding the bottle production envelope. Pharmaceutical regulators do not accept “we change the oil regularly” as a control — they require the contamination pathway not to exist architecturally.

Korean Ever-Power EV platforms eliminate hydraulic systems entirely. All motion axes — clamping, injection, stretch, ejection, gate-cutting, indexing — operate on servo-electric drives. There is zero hydraulic fluid anywhere in the production envelope. The only fluids present are mould cooling water (sealed in stainless circulation circuits) and compressed air (HEPA-filtered for cleanroom service). The full all-servo architecture rationale is documented in our 全サーボ式電気自動車ISBM 40%のエネルギー解析.

For Korean pharmaceutical producers, the 40% energy savings of all-servo is a secondary benefit — the primary benefit is regulatory acceptability. All-servo machines pass cleanroom audits; hydraulic machines fundamentally cannot.

6. ISO 7 vs. ISO 8 Cleanroom Integration Requirements

Korean pharmaceutical bottle production typically operates in either ISO Class 7 (10,000-class equivalent) or ISO Class 8 (100,000-class equivalent) cleanrooms, depending on the downstream fill application.

ISO Class 8 Standard Pharmaceutical Production

ISO 8 supports non-sterile oral medication, OTC supplements, syrups, and most pharmaceutical primary packaging where the bottle will be sealed before contamination becomes an issue. Standard Korean Ever-Power EV platforms in standard configuration meet ISO 8 requirements out of the box: HEPA-filtered air circulation, cleanable machine surfaces, sealed lubrication systems, and operator-removed exposure during normal cycle.

ISO Class 7 Sterile-Adjacent Production

ISO 7 supports sterile-fill applications including unpreserved eye drops, parenteral products, and sterile irrigation solutions. Korean Ever-Power EV platforms can be configured for ISO 7 with additional specifications: SS316L surface materials throughout the production envelope (vs. standard SS304), HEPA-filtered compressed air at higher specification, machine internal surfaces specifically validated for cleanability per ASTM standards, and integration with cleanroom HVAC for differential pressure management.

Korean producers entering ISO 7 production should plan additional 8–14 weeks of validation work beyond standard commissioning, plus regulatory documentation supporting the cleanroom integration. The systematic approach is part of our 10-factor ISBM machine decision framework.

7. KFDA Article 6, FDA 21 CFR, EU 10/2011 Compliance Architecture

Korean pharmaceutical producers selling domestically and exporting face a stack of regulatory standards that machine architecture must support. Korean Ever-Power’s standard documentation pack covers each.

KFDA Article 6 (Korea): mandatory for all pharmaceutical packaging sold in Korea. Requires documented food/pharma-contact compatibility, migration testing, and supplier audit responses. Korean Ever-Power machines ship with KFDA-compliant material certification and standard validation protocols.

FDA 21 CFR 174-178 (USA): required for export to North American markets. Covers indirect food/drug additives, including PET (177.1630), PETG (177.1660), and other resins. Documentation pack supports US import audit.

EU 10/2011 (Europe): required for European pharmaceutical export. Includes specific migration limits and overall migration limits for plasticizers, residual monomers, and thermal degradation products.

Japan JFSL Article 18: required for Japanese pharmaceutical export. Korean producers exporting to Japan via the Korean major partnerships need this documentation track.

WHO GMP / PIC/S guidelines: referenced by Korean MFDS for GMP inspection consistency. Korean Ever-Power IQ/OQ/PQ documentation aligns with PIC/S inspection patterns.

8. Sterile-Fill Compatibility: Closed-Cycle Production

For sterile-fill applications — eye drops, parenteral solutions, sterile irrigation — bottle production must integrate seamlessly with downstream sterile-fill systems. This integration imposes additional architectural requirements beyond standard cleanroom production.

No-Touch Bottle Transfer

From the moment the bottle is ejected from the ISBM machine until it reaches the sterile-fill needle, it must be transported through closed conveyor systems with no human contact. Korean Ever-Power EV platforms include automatic bottle ejection into sealed conveyor systems supporting this no-touch requirement.

Bottle Interior Sterility Pathway

For unpreserved sterile-fill applications, the bottle interior should never see particulate or microbial contamination from the moment of formation. The all-servo One-Step architecture supports this because the bottle interior is shaped against the mould cavity (sterile by design), then sealed environment until fill. Two-Step bottles cannot meet this requirement because the interior was at one point a preform exterior exposed to bin storage.

Validated Bioburden Limits

Sterile-fill operations require validated bioburden limits on incoming bottles — typical specification <10 CFU per bottle pre-sterilization. Korean Ever-Power machines support this via cleanroom integration, sealed bottle handling, and the architecturally-controlled contamination pathway. The systematic preventive approach lives in our 5段階予防保全フレームワーク.

9. Korean Pharma Customer Validation: IQ / OQ / PQ Path

Selling pharmaceutical bottles to Daewoong, Yuhan, JW Pharm, Hanmi Pharm, or similar Korean majors requires completing a structured supplier validation including Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ).

IQ — Installation Qualification. Documents that the equipment was installed correctly per specification. Includes utility tie-in records, calibration certificates for all sensors, software version documentation, and complete materials of construction certification. Korean Ever-Power supplies the full IQ documentation pack at delivery.

OQ — Operational Qualification. Demonstrates that equipment operates per specification across the validated operational range. Includes temperature stability tests, pressure repeatability, motion accuracy across full stroke, and process parameter range verification. OQ runs typically span 3–7 days of structured testing.

PQ — Performance Qualification. Demonstrates that the validated equipment produces compliant product reliably. Typically 3 consecutive successful production lots of 50,000–250,000 bottles each, with full dimensional, weight, optical, and migration test results documented. PQ typically spans 4–8 weeks.

Korean Ever-Power’s pharma-segment customer support includes engineering presence during IQ/OQ/PQ to assist customer documentation and address any unexpected findings. This support is included with every all-servo platform sold for pharmaceutical applications.

10. Korean Ever-Power Pharmaceutical Implementation Roadmap

From decision to commercial pharmaceutical bottle production typically runs 9–14 months on a structured Korean Ever-Power implementation:

Stage 1 — Customer portfolio analysis (weeks 1–4). Korean Ever-Power engineers analyze your target Korean pharmaceutical customer portfolio, SKU specifications, regulatory targets (KFDA only vs. FDA / EU additional), and cleanroom requirements (ISO 7 vs. ISO 8). Output: machine specification, mould tooling plan, regulatory documentation strategy.

Stage 2 — Machine + mould turnkey manufacture (weeks 4–18). Standard 90-day platform manufacture at Ansan-si; pharma-specific mould tooling parallel manufacture with SS316L inserts where required.

Stage 3 — PAT at Ansan-si (week 19). Customer-attended Pre-Acceptance Testing with full documentation generation supporting eventual IQ submission to your Korean pharma customer.

Stage 4 — Cleanroom installation (weeks 20–24). Cleanroom integration is more involved than standard installation — typically 14–28 days vs. 7–14 for standard ISBM. Includes utility tie-in, cleanroom-grade compressed air integration, HVAC differential pressure verification, and IQ documentation generation.

Stage 5 — OQ runs (weeks 25–28). Korean Ever-Power engineering on-site to support customer OQ protocol execution.

Stage 6 — PQ runs and customer audit (weeks 29–52). PQ runs producing first commercial lots with customer attendance and approval. Customer-side regulatory documentation preparation. First commercial shipment to Korean pharma customer typically week 38–52 depending on customer timing.